This Article  • References  • Full text PDF  • Reply to article  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on Web of Science (8)  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Social Bookmarking   What's this?

A European Perspective

Fritz A. Henn, PhD, MD
University of Heidelberg Central Institute of Mental Health Postfach 12 21 20 68072 Mannheim, Germany

Malcolm Lader, OBE, DSc, PhD, FRCPsych
London, England

Hanfried Helmchen, MD
Berlin, Germany

Arch Gen Psychiatry. 1997;54(5):412-413.

	Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings.

THE ARTICLE by Carpenter et al¹ in this issue of the ARCHIVES presents a clear evaluation of the role of medication-free research in schizophrenia and discusses the ethical implications of such research. The authors argue that medication-free research offers distinct advantages in treatment trials and that the risks for relapse can be limited through careful patient selection, close clinical monitoring, and psychosocial treatments. They further discuss the role of medication-free research in probing questions concerning etiology and provide some assessment of the issues in determining the risk-to-benefit ratio in these cases. They also suggest some relevant guidelines for patient selection in carrying out medication-free research. Finally, they provide some thoughtful insights on the issue of informed consent. They conclude that medication-free research in schizophrenia is clearly worthwhile and even necessary in treatment evaluations and in studies aimed at understanding etiology and that reasonable guidelines should be established by . . . [Full Text PDF of this Article]

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?